By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR)
On March 22, 2023, the U.S. Food and Drug Administration granted accelerated approval to retifanlimab-dlwr — a humanized monoclonal antibody that targets
The International Innovation Grant will Fund Research on the Effectiveness of Community Screening Programs for the Early Detection of Oral Cancers in
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center The Zuma 7 trial is a randomized, open-label multicenter study for
By Dr. Dipesh Uprety Karmanos Cancer Institute
By Dr. Radhika Kulkarni Henry Ford Cancer Institute On March 2nd, 2023, results of the Phase 2 trial, SWOG 1801, (NCT03698019)
On March 16, 2023, the U.S. Food and Drug Administration approved dabrafenib and trametinib for pediatric patients 1 year of age and
By Dr. Dipesh Uprety Karmanos Cancer Institute While immunotherapy is being used religiously for non-oncogene-addicted advanced non-small cell lung cancer, the
By Dr. Kanak Parmar Texas Tech University Perioperative systemic therapy for resectable non-small cell lung cancer Surgical resection followed by adjuvant
By Dr. Tarik Hadid Wayne State University Human papillomavirus (HPV) is a small DS-DNA virus, and humans are the only known